Bristol Myers Squibb bids farewell to dealmaking czar Elizabeth Mily

Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker.

Elizabeth Mily, who replaced BMS’ former M&A czar Paul Biondi back in 2020, is headed for the exit, the company confirmed Friday.

Mily joined the pharma company in spring of 2020 from Barclays, where she served as managing director and chair of life sciences and oversaw some $200 billion in completed mergers and acquisitions.